Bayer's Balancing Act: $5 Billion in Legal Outflows vs. a Pipeline Revival
Published on 06/24/2026 at 16:42 | Redaktion boerse-global.de
Bayer’s investors are staring down a year of punishing cash outflows. The Leverkusen-based drugmaker expects free cash flow to slump as low as minus €2.5 billion in 2026, weighed down by roughly €5 billion in litigation payments tied to the ongoing glyphosate saga. That drain sits alongside a net debt pile of around €33 billion, forcing the group to pin its hopes on a string of pipeline catalysts and a pivotal US Supreme Court ruling on whether federal pesticide approvals can preempt state-level warning claims.
A decision in the “Durnell” case could come as early as this week. If the justices side with Bayer, the move would effectively gut the remaining glyphosate lawsuits — a structural win that analysts say would be worth billions in avoided liabilities. The stock shot up nearly 4% on the anticipation, hitting €40.03, though it still sits about 20% below its 52-week high of €49.93.
Across the Atlantic, a separate threat has emerged. On June 18, the Trump administration launched a Section 301 trade investigation targeting Germany’s drug pricing policies, arguing that low reimbursement levels force US patients to shoulder a disproportionate share of global R&D costs. US Trade Representative Greer has floated higher German prices as an alternative to tariffs. A public hearing is scheduled for September. For Bayer, which operates manufacturing and sales on both sides of the Atlantic, any new duties or forced price adjustments would squeeze pharma margins directly.
Should investors sell immediately? Or is it worth buying Bayer?
On the operational front, there are bright spots. The FDA cleared Bayer’s contrast agent Ambelvist (gadoquatrane) for MRI imaging on June 15 — both for adults and paediatric patients including newborns. The agent contains 60% less gadolinium than comparable macrocyclic products. Japan had already approved it in March, while applications are pending in Europe and China. Meanwhile, the oral Factor XIa inhibitor asundexian is under review by the EMA and FDA. Phase III data showed a 26% risk reduction versus placebo, offering a potential successor to Xarelto, whose sales plunged by a third to $2.6 billion in 2025 after patent expiry. At the ASCO annual meeting, Bayer also showcased 16 new research projects, including a Phase II trial (ARACOG) that pits its prostate cancer drug Nubeqa directly against enzalutamide.
Those pipeline wins help offset a mixed quarterly picture. First-quarter 2026 revenue rose 4.1% currency-adjusted to €13.4 billion, with EBITDA before special items up 9% to €4.5 billion. Nubeqa surged 57% and Kerendia climbed 84%. Yet the group still expects full-year sales growth of no more than 3% on a currency-adjusted basis. Outside pharma, Bayer is pushing into new markets: its Indian subsidiary has relaunched Alka-Seltzer with probiotics, targeting the ayurvedic self-medication segment.
Technical indicators reflect the cautious optimism. The stock has recovered sharply from its August lows, now sitting nearly 9% above its 200-day moving average. The relative strength index reads 64.3, signalling upside momentum but not yet overbought. Whether that momentum can carry Bayer to retest its 52-week high depends on the Supreme Court’s verdict — and on whether the pipeline can deliver enough to offset the billions still flowing out the door.
Ad
Bayer Stock: New Analysis - 24 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
